Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    85,538.84
    +4,709.95 (+5.83%)
     

  • CMC Crypto 200

    1,363.86
    +86.88 (+6.80%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Today's Research Reports on Microbix Biosystems, Essa Pharma, Calyx Bio-Ventures and Revive Therapeutics

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / October 3, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Microbix Biosystems Inc.
https://rdinvesting.com/news/?ticker=MBX.TO

Essa Pharma Inc.
https://rdinvesting.com/news/?ticker=EPI.TO

Calyx Bio-Ventures Inc.
https://rdinvesting.com/news/?ticker=CYX.V

Revive Therapeutics Ltd.
https://rdinvesting.com/news/?ticker=RVV.V

ADVERTISEMENT

Microbix Biosystems Inc.'s stock moved 8.11% lower Monday, to close the day at $0.34. The stock recorded a trading volume of 48,100 shares, which was below its three months average volume of 50,373 shares. In the last year, Microbix Biosystems Inc.'s shares have traded in a range of 0.18 - 0.40. The share price has gained 88.89% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.34 is greater than its 200-day moving average of $0.30. Shares of Microbix Biosystems have gained approximately 33.33 percent year-to-date.

Access RDI's Microbix Biosystems Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MBX.TO

On Monday, shares in Essa Pharma Inc. recorded a trading volume of 5,300 shares, which was below the three months average volume of 200,286 shares. The stock ended the day flat at 0.36. The stock is currently trading 90.58% below its 52-week high with a 52-week trading range of 0.33 - 3.82.The company's shares are currently trading at their 200-day moving average. Moreover, the stock's 50-day moving average of $0.36 is at its 200-day moving average of $0.36. Shares of Essa Pharma have fallen approximately 87.8 percent year-to-date.

Access RDI's Essa Pharma Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EPI.TO

Calyx Bio-Ventures Inc.'s stock fell 17.65% Monday, to close the day at $0.07. The stock recorded a trading volume of 527,216 shares, which was above its three months average volume of 406,895 shares. In the last year, Calyx Bio-Ventures Inc.'s shares have traded in a range of 0.04 - 0.16. The share price has gained 75.00% from its 52 week low. The company's shares are currently trading at their 200-day moving average. Moreover, the stock's 50-day moving average of $0.06 is below its 200-day moving average of $0.07. Shares of Calyx Bio-Ventures have fallen approximately 6.67 percent year-to-date.

Access RDI's Calyx Bio-Ventures Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CYX.V

On Monday, shares in Revive Therapeutics Ltd. recorded a trading volume of 922,950 shares, which was above the three months average volume of 162,659 shares. The stock ended the day 8.57% higher at 0.19. The share price has gained 100.00% from its 52-week low with a 52-week trading range of 0.09 - 0.44.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.17 is below its 200-day moving average of $0.20. Shares of Revive Therapeutics have gained approximately 65.22 percent year-to-date.

Access RDI's Revive Therapeutics Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=RVV.V

Our Actionable Research on Microbix Biosystems Inc. (TSX: MBX.TO), Essa Pharma Inc. (TSX: EPI.TO), Calyx Bio-Ventures Inc. (TSX-V: CYX.V) and Revive Therapeutics Ltd. (TSX-V: RVV.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com